SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 117 filers reported holding SYNDAX PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 1.53 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,520,000 | -25.0% | 1,000,000 | +8.1% | 0.03% | -21.4% |
| Q2 2023 | $19,360,250 | +16.0% | 925,000 | +17.1% | 0.04% | +13.5% |
| Q1 2023 | $16,684,800 | -30.3% | 790,000 | -16.0% | 0.04% | -35.1% |
| Q4 2022 | $23,923,000 | -20.4% | 940,000 | -24.8% | 0.06% | -23.0% |
| Q3 2022 | $30,038,000 | +26.2% | 1,250,000 | +1.0% | 0.07% | +34.5% |
| Q2 2022 | $23,806,000 | +27.0% | 1,237,300 | +14.7% | 0.06% | +52.8% |
| Q1 2022 | $18,747,000 | -28.6% | 1,078,641 | -10.1% | 0.04% | -23.4% |
| Q4 2021 | $26,268,000 | -52.0% | 1,200,000 | -58.1% | 0.05% | -56.5% |
| Q3 2021 | $54,774,000 | +28.1% | 2,866,272 | +15.1% | 0.11% | +28.6% |
| Q2 2021 | $42,775,000 | +9.3% | 2,491,272 | +42.4% | 0.08% | +5.0% |
| Q1 2021 | $39,130,000 | -3.9% | 1,750,000 | -4.4% | 0.08% | -10.1% |
| Q4 2020 | $40,709,000 | +62.2% | 1,830,439 | +7.7% | 0.09% | +41.3% |
| Q3 2020 | $25,092,000 | +61.2% | 1,700,000 | +61.9% | 0.06% | +57.5% |
| Q2 2020 | $15,561,000 | +41.9% | 1,050,000 | +5.0% | 0.04% | +21.2% |
| Q1 2020 | $10,970,000 | -0.0% | 1,000,000 | -20.0% | 0.03% | +22.2% |
| Q4 2019 | $10,975,000 | +17.5% | 1,250,000 | 0.0% | 0.03% | +17.4% |
| Q3 2019 | $9,338,000 | -32.0% | 1,250,000 | -15.3% | 0.02% | -32.4% |
| Q2 2019 | $13,732,000 | +68.7% | 1,475,000 | -4.8% | 0.03% | +70.0% |
| Q1 2019 | $8,138,000 | – | 1,550,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |